scholarly journals Prognostic Significance of plasma albumin to fibrinogen ratio Associated Nomograms in Patients with breast invasive ductal carcinoma

2019 ◽  
Author(s):  
Lihua Zheng ◽  
Feng Liu ◽  
Yaheng Zhao ◽  
Wei Li ◽  
Yan Yang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Invasive Ductal Carcinoma ◽  
Predictive Accuracy ◽  
Ductal Carcinoma ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Metastatic Breast ◽  
Survival Outcomes ◽  
Plasma Albumin ◽  
Breast Invasive Ductal Carcinoma

Abstract Background : In the context of breast invasive ductal carcinoma, this research aims to retrospectively evaluate by preoperative plasma albumin to fibrinogen ratio (AFR) and forecast oncological outcome and recurrence. Methods : This reflective study included 230 patients who had surgical procedures at the Fourth Hospital of Hebei Medical University between January 2009 and April 2012 for the treatment of their non-metastatic breast invasive ductal carcinoma. We utilized an optimal value of preoperative plasma fibrinogen and albumin for the patient classification. Additionally, we used the Kaplan-Meier method to extensively evaluate progression-free and cancer-specific survival outcomes. The analysis of the linkages between the albumin to fibrinogen ratio and clinical outcomes was executed through the univariate and multivariate analyses. To construct nomograms and evaluate the survival outcomes, we used a variety of risk factors. We also verified the predictive accuracy through the Harrell's concordance index (C-index). Results : The association of plasma AFR with diminished disease-free survival (DFS) and overall survival (OS) is statistically significant. An independent prognostic indicator is the plasma AFR, as reported by the multivariate analysis, for DFS (HR =1.346; 95% CI:1.107-1.636; p = 0.03) and overall survival (OS) (HR = 1.485; 95% CI: 1.106-1.993; p = 0.008). Two prediction model of OS and DFS based on the AFR was developed. Conclusions : For patients with breast invasive ductal carcinoma, an independent prognostic factor for the outcomes of oncology patients is the elevated preoperative plasma AFR. For DFS and OS, the constructed nomogram demonstrated highly significant predictive accuracy.

scholarly journals Impact of Post-diagnosis Weight Change on Survival Outcomes in a Multiethnic Cohort of Breast Cancer Patients

2020 ◽  
Author(s):  
Lihua Shang ◽  
Masaya Hattori ◽  
Gini Fleming ◽  
Nora Jaskowiak ◽  
Donald Hedeker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Weight Change ◽  
Repeated Measures ◽  
Disease Free Survival ◽  
Metastatic Breast ◽  
Survival Outcomes ◽  
Breast Cancer Patients ◽  
Increased Risk

Abstract Purpose: To evaluate weight change patterns over time following the diagnosis of breast cancer, and to examine the association of post-diagnosis weight change and survival outcomes in Black and White patients.Methods: The study included 2,888 women diagnosed with non-metastatic breast cancer in 2000-2017 in Chicago. Longitudinal repeated measures of weight and height were collected, along with a questionnaire survey including questions on body size. Multilevel mixed-effects models were used to examine changes in body mass index (BMI). Delayed entry Cox proportional hazards models were used to investigate the impacts of changing slope of BMI on survival outcomes. Results: At diagnosis, most patients were overweight or obese with a mean BMI of 27.5 kg/m2 and 31.5 kg/m2 for Blacks and Whites, respectively. Notably, about 45% of the patients had cachexia before death and substantial weight loss started about 30 months before death. In multivariable-adjusted analyses, compared to stable weight, BMI loss (>0.5 kg/m2/year) showed greater than 2-fold increased risk in overall survival (hazard ratio [HR]=2.68, 95%CI 1.95-3.66), breast cancer specific survival (HR=2.93, 95%CI 1.86-4.62), and disease-free survival (HR=2.25, 95%CI 1.63-3.11). The associations were not modified by race, age at diagnosis, and pre-diagnostic weight. BMI gain (>0.5 kg/m2/year) was also related to worse survival, but the effect was weak (HR=1.53, 95%CI 1.06-2.22 for overall survival).Conclusion: BMI loss is a strong predictor of worse breast cancer outcomes. Growing prevalence of obesity may hide diagnosis of cancer cachexia, which can occur in a large proportion of breast cancer patients long before death.

scholarly journals The prognostic value and immune microenvironment association of androgen receptor in HER2 positive early breast invasive ductal carcinoma

2021 ◽  
Author(s):  
Danyang Zhou
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Negative Correlation ◽  
Prognostic Value ◽  
Ductal Carcinoma ◽  
Disease Free Survival ◽  
Immune Microenvironment ◽  
Breast Invasive Ductal Carcinoma ◽  
Kaplan Meier

Abstract BackgroundThe prognosis of HER2+ early breast cancer is heterogeneous. AR, as an indicator of prognosis and treatment, is uncertain in HER2+ subtypes. We aimed to investigate the prognostic value of AR and the relationship between AR expression and immune microenvironment in HER2+ early breast invasive ductal carcinoma (IDC).MethodsHER2+ early breast IDC patients diagnosed by pathology who underwent surgery at Sun Yat-sen University Cancer Center from 2016 to 2017 were the main population. All patients included performed AR test and their clinicopathological data were collected. The disease-free survival (DFS) and overall survival (OS) were evaluated by the Kaplan–Meier method and Cox proportional hazards model. AR+ and AR- breast IDCs were matched 1:1 according to age, T stage and N stage for immune infiltration analysis.ResultsA total of 554 patients with HER2+ early breast cancer were included in this retrospective study, regardless of HR status. Taking 10% as the cutoff values of AR, 81.6% of patients were AR positive and 18.4% were AR negative. ER+ (P<0.001) and PR+ (P<0.001) had significant relations with the positive expression of AR. Kaplan-Meier survival curves analysis suggested that AR had close links with OS (P=0.001), not DFS (P=0.051). Eliminating the potential impact caused by HR, AR also predicted a longer OS (P=0.014) and AR was an independent impact factor for OS by multivariate analysis (P=0.036) in HER2+HR- early breast IDC patients. In AR+ and AR- matched HER2+HR- patients, TILs (P=0.043) and PD-L1 (P=0.027) is significantly low in AR+ patients. The strongest negative correlation was observed between AR and PD-L1 (Pearson’s r =-0.299, P=0.001). AR+ seemed to trend a favorable clinical survival in HER2+HR- IDCs with low TILs or positive PD-L1.ConclusionsAR+ were markedly related to the better OS in HER2+HR- early breast cancer, while the negative correlation was observed between AR and PD-L1/TILs. We provided new insights for the prognostic value and immune microenvironment association of AR to optimize treatment strategies in HER2+ early breast IDCs.

Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer

2011 ◽  
Vol 236 (2) ◽  
pp. 145-155 ◽  
Author(s):  
Geetika Chakravarty ◽  
Krzysztof Moroz ◽  
Nick M Makridakis ◽  
Shelby Alaine Lloyd ◽  
Sarah E Galvez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Prognostic Significance ◽  
Metastatic Breast

scholarly journals The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 3963
Author(s):  
Brendah K. Masisi ◽  
Rokaya El Ansari ◽  
Lutfi Alfarsi ◽  
Madeleine L. Craze ◽  
Natasha Jewa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Patient Outcome ◽  
Ductal Carcinoma ◽  
Tumour Size ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Glutamine Metabolism ◽  
Gene Copy ◽  
Luminal Breast Cancer ◽  
Potential Biomarker

The glutamine metabolism has a key role in the regulation of uncontrolled tumour growth. This study aimed to evaluate the expression and prognostic significance of glutaminase in luminal breast cancer (BC). The glutaminase isoforms (GLS/GLS2) were assessed at genomic/transcriptomic levels, using METABRIC (n = 1398) and GeneMiner datasets (n = 4712), and protein using immunohistochemistry in well-characterised cohorts of Oestrogen receptor-positive/HER2-negative BC patients: ductal carcinoma in situ (DCIS; n = 206) and invasive breast cancer (IBC; n = 717). Glutaminase expression was associated with clinicopathological features, patient outcome and glutamine-metabolism-related genes. In DCIS, GLS alone and GLS+/GLS2- expression were risk factors for shorter local recurrence-free interval (p < 0.0001 and p = 0.001, respectively) and remained prognostic factors independent of tumour size, grade and comedo necrosis (p = 0.0008 and p = 0.003, respectively). In IBC, GLS gene copy number gain with high mRNA expression was associated with poor patient outcome (p = 0.011), whereas high GLS2 protein was predictive of a longer disease-free survival (p = 0.006). Glutaminase plays a role in the biological function of luminal BC, particularly GLS in the early non-invasive stage, which could be used as a potential biomarker to predict disease progression and a target for inhibition. Further validation is required to confirm these observations, and functional assessments are needed to explore their specific roles.

Sign in / Sign up

Export Citation Format

Share Document